January 21, 2022 05:16 AM ESTUpdated 01:17 PM

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

→ The needle on the Maraganore Meter is moving again, as John Maraganore keeps collecting more post-Alnylam roles. First, he and BeiGene co-founder Peter Ho …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA

Alex Hoffman

Copy Chief

Kathy Wong

Editor

Derek Graf

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

CBER's deputy director departs as staff shakeup continues

Bluebird bio to sell to investment funds after struggling to make money from gene therapies

Eli Lilly stockpiles $548M of oral weight loss drug ahead of launch

FDA approves first drug to treat ultra-rare lipid storage disease

Will CRISPR matter?

Trusted protection: Why the current meningococcal vaccination schedule shouldn’t change without strong evidence

As Hal Bar­ron steals the show, there’s no off po­si­tion on the John Maraganore switch; Dan­ny Bar-Zo­har makes an­oth­er leap for­ward at Mer­ck KGaA

Copy Chief

Editor

Sign up to read this article for free.

Bachem

Bubendorf, BL, Switzerland

As Hal Barron steals the show, there’s no off position on the John Maraganore switch; Danny Bar-Zohar makes another leap forward at Merck KGaA